Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

 
• By Alaric DeArment

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

3d illustration of T cells or cancer cells
Fate Therapeutics presented early data at ASCO on its NK cell therapy program • Source: Shutterstock

More from ASCO

More from Conferences